Prosecution Insights
Last updated: August 08, 2026

Ludwig Institute for Cancer Research Ltd.

6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
3
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (33%)
4
Medium (67%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (33%)
Double-patenting + other2 (33%)
Multi-statute (no §101)2 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
KIM, SEONG JONG 1
STAVROU, CONSTANTINA E 1 44.2% +36.3%
ROGERS, ERIC JASON 1 57.3% +30.6%
KIM, TAEYOON 1 51.5% +51.8%
BUCHANAN, BAILEY CHEYENNE 1 47.6% +50.0%
PHAM, KHAI QUYNH TIEN 1 0.0% +0.0%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18579221 Use Of Methanol And Prodrugs Thereof In Therapy KIM, SEONG JONG
18558802 UROLITHIN FOR INCREASING STEM CELL FUNCTION STAVROU, CONSTANTINA E
18001898 PARALLEL ANALYSIS OF INDIVIDUAL CELLS FOR RNA EXPRESSION AND DNA FROM TARGETED TAGMENTATION BY SEQUENCING PHAM, KHAI QUYNH TIEN

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18246744 COMPOSITIONS AND METHODS FOR INCREASING STEM CELL FUNCTION ROGERS, ERIC JASON 2d overdue
18558802 UROLITHIN FOR INCREASING STEM CELL FUNCTION STAVROU, CONSTANTINA E
18246710 COMPOSITIONS AND METHODS FOR INCREASING STEM CELL FUNCTION KIM, TAEYOON
18026166 CYTOSINE MODIFICATION ANALYSIS BUCHANAN, BAILEY CHEYENNE

Top Art Units

Art UnitApps
1621 1
1632 1
1638 1
1631 1
1682 1
1684 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18579221 Use Of Methanol And Prodrugs Thereof In Therapy KIM, SEONG JONG 1621 §103§112 Non-Final OA Pending Jan 12, 2024
18558802 UROLITHIN FOR INCREASING STEM CELL FUNCTION STAVROU, CONSTANTINA E 1632 §102§103§112Other Non-Final OA Pending Nov 03, 2023
18246744 COMPOSITIONS AND METHODS FOR INCREASING STEM CELL FUNCTION ROGERS, ERIC JASON 1638 §103§112DP Final Rejection 2d overdue Pending Mar 27, 2023
18246710 COMPOSITIONS AND METHODS FOR INCREASING STEM CELL FUNCTION KIM, TAEYOON 1631 §103DP Final Rejection Pending Mar 27, 2023
18026166 CYTOSINE MODIFICATION ANALYSIS BUCHANAN, BAILEY CHEYENNE 1682 §103 Final Rejection Pending Mar 14, 2023
18001898 PARALLEL ANALYSIS OF INDIVIDUAL CELLS FOR RNA EXPRESSION AND DNA FROM TARGETED TAGMENTATION BY SEQUENCING PHAM, KHAI QUYNH TIEN 1684 §103 Non-Final OA Pending Dec 15, 2022

Managing Ludwig Institute for Cancer Research Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month